Utilizing multiple datasets, including GSE21034, DKFZ2018, and TCGA-PRAD cohorts, we compared the expression levels of AZGP1 across different T stages, N status, Gleason scores, and tumor mutation burdens (TMB). Here, AZGP1 is linked to prostate adenocarcinoma.